Abstract
This study investigates the combined effects of human-derived Limosilactobacillus fermentum and Lactiplantibacillus plantarum with the prebiotic inulin (LI) on type 2 diabetes mellitus (T2DM) in db/db mice. Over a 12-week period, the LI intervention significantly reduced fasting blood glucose levels and improved colon tissue integrity compared to diabetic controls. Multi-omics analysis revealed that LI treatment reshaped the gut microbiota—decreasing pathogens like Corynebacterium and Proteus while restoring beneficial genera—and normalized metabolic pathways related to tryptophan and linoleic acid. These findings suggest that synbiotic interventions can effectively manage T2DM by modulating the gut-metabolism axis.
Introduction
Type 2 Diabetes Mellitus (T2DM) is a global health challenge characterized by chronic hyperglycemia and metabolic dysfunction. Recent research highlights the critical role of gut dysbiosis—an imbalance in intestinal microbial communities—in the progression of T2DM. While probiotics and prebiotics have been studied individually, their synergistic "synbiotic" potential offers a more robust approach to restoring intestinal homeostasis. This study explores how a specific combination of human-derived Lactobacillaceae and inulin can mitigate diabetic symptoms by rewiring the gut's microbial and metabolic landscape.
Methods and Experimental Design
The researchers utilized db/db mice, a well-established genetic model for T2DM. The mice were categorized into four groups: a normal control (NC), a diabetic model control (MC), a probiotic cocktail group (L), and a probiotics plus 5% inulin group (LI). The 12-week intervention was evaluated using a multi-omics framework including 16S rRNA sequencing for microbiota profiling and untargeted metabolomics for cecal metabolite identification.
Key Results
Improved Glucose Regulation and Intestinal Health
The most prominent physiological outcome was the significant reduction in fasting blood glucose (FBG) in the LI group compared to the MC group. Furthermore, the synbiotic treatment preserved the structural integrity of the colon, preventing the thinning of the intestinal wall and reducing inflammatory infiltration typically seen in diabetic models.
Reshaping the Gut Microbiota
The LI intervention effectively suppressed opportunistic pathogens such as Corynebacterium and Proteus. Simultaneously, it restored key beneficial genera, including Lachnospiraceae and Lachnoclostridium. Diversity analysis and community clustering confirmed that the LI treatment shifted the diabetic microbiome toward a state more similar to the healthy control.
Metabolic Pathway Normalization
The study identified 138 differential metabolites, with LI treatment reversing the abnormal levels of L-phenylalanine and L-tryptophan found in diabetic mice. Specifically, LI normalized the "serotonergic synapse" pathway and restored levels of 13(S)-HpODE, a signaling molecule involved in linoleic acid metabolism. Additionally, LI significantly boosted levels of short-chain fatty acids (SCFAs), which are vital for improving insulin sensitivity.
Discussion and Future Directions
The synergistic effect of Lactobacillaceae and inulin proves more effective than probiotics alone, suggesting that the prebiotic fiber provides a necessary substrate for the beneficial bacteria to thrive. While these results are promising, the study's reliance on a mouse model necessitates future clinical trials. Further research using fecal microbiota transplantation (FMT) is also required to establish direct causality between specific microbes and metabolic improvements. These results provide a foundation for developing synbiotic-based therapies for T2DM management.
Summary updated